137
Views
7
CrossRef citations to date
0
Altmetric
Research Articles

Is Monogamy or Committed Relationship Status a Marker for Low Sexual Risk among Men in Substance Abuse Treatment? Clinical and Methodological Considerations

, Ph.D., , Ph.D., , Ph.D. & , Ph.D.
Pages 294-300 | Published online: 22 Aug 2011
 

Abstract

Background: HIV prevention interventions often promote monogamy to reduce sexual risk. However, there is little consensus about how to define monogamy. Objective: To determine the extent to which recent monogamy and/or being in a committed relationship serve as markers for low sexual risk among men in substance abuse treatment. Methods: Participants were 360 men enrolled in the National Institute on Drug Abuse Clinical Trials Network “Real Men Are Safe” protocol who completed all assessments (baseline, 3 months, and 6 months). Self-reported behaviors included number of sexual partners, type of relationships, frequency of vaginal/anal intercourse, and percentage of condom use. Results: The rate of self-reported monogamy in the prior 90 days was stable across assessments (54.2%, 53.1%, 58.3%). However, at each assessment 7.5–10% of monogamous men identified their partner as a casual partner, and only 123 (34.2%) reported being monogamous at every assessment. Of these, 20 (5.6%) reported being monogamous with different partners across assessments. Men with both committed relationship and casual partners reported more condom use with their committed relationship partners than men with only a committed relationship partner. Conclusion: Clinicians and researchers should consider individual relationship context and behavior and avoid assuming that recent monogamy or being in a committed relationship denotes low risk. Scientific Significance: This study provides evidence that, in male drug users, monogamy does not necessarily reflect low sexual risk. Rather, “monogamous” men actually encompass various combinations of partner types and levels of risk behavior that are unstable, even over brief time periods. Clinicians and researchers must take these variations into account.

Trial registration: ClinicalTrials.gov identifier: NCT00084175.

ACKNOWLEDGEMENTS

The authors wish to thank the research staff and participants at each of the 14 participating treatment programs. This study was supported by the NIDA CTN grants: U10 DA13714, U10 DA13035. The trial is registered with ClinicalTrials.gov (http://www.clinicaltrials.gov/), a service of the US National Institutes of Health (number: NCT00084175).

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.